echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Neurology: Should dual antiplatelet therapy be switched to cilostazol after 2 weeks?

    Neurology: Should dual antiplatelet therapy be switched to cilostazol after 2 weeks?

    • Last Update: 2022-05-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compared with aspirin (ASA) monotherapy, dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel (ASA+CLO) reduces the risk of early recurrent stroke after minor ischemic stroke or high-risk TIA, but the first The effect of DAPT on stroke risk reduction gradually diminished after one month, and from then on also increased the risk of major bleeding (vs ASA)


    stroke

    Another DAPT is a dual antiplatelet strategy based on cilostazol (CLZ).


    In March 2022, Kazunori Toyoda et al.


    In March 2022, Kazunori Toyoda et al.


    Of the 1879 patients, 498 belonged to the 8-14 day group, 467 belonged to the 15-28 day group, and 914 belonged to the 29-180 day group


    For recurrent ischemic stroke, there was a significant treatment-by-subgroup interaction between the trial treatment groups and the three groups


    The authors concluded that a long-term DAPT (cilostazol-containing) strategy initiated 15-180 days after stroke was more effective in secondary stroke prevention than DAPT (cilostazol-containing) initiated 8-14 days after stroke ( vs single agent) and did not increase the risk of bleeding


    A long-term DAPT (with cilostazol) strategy initiated 15-180 days after onset was more effective in secondary stroke prevention compared with initiation of DAPT (with cilostazol) 8-14 days after stroke (vs single agent) , and did not increase the risk of bleeding prophylaxis

    Original source:

    Original source:

    Kazunori Toyoda, Katsuhiro Omae, Haruhiko Hoshino, et al.


    Association of Timing for Starting Dual Antiplatelet Treatment With Cilostazol and Recurrent Stroke: A CSPS.
    com Trial Post Hoc Analysis.


    Leave a Comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.